Reduction of cortical TrkA but not p75 NTR protein in early-stage Alzheimer's disease

Annals of Neurology

Volumn 56, Issue 4, 2004, Pages 520-531

  Counts, Scott E ^a   Nadeem, Muhammad ^a   Wuu, Joanne ^a   Ginsberg, Stephen D ^b   Saragovi, H Uri ^c   Mufson, Elliott J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PROTEIN P75;

AGED; ALZHEIMER DISEASE; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MENTAL HEALTH; MENTAL TEST; OLIVARY NUCLEUS; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPORAL CORTEX; VISUAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CELL COUNT; CELL LINE, TUMOR; CEREBRAL CORTEX; COGNITION DISORDERS; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; NEUROPSYCHOLOGICAL TESTS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR;

EID: 4644268336     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20233     Document Type: Article

References (77)

1. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by rhe basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-197.
2. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163:495-529.
3. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219: 1184-1190.
4. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol 1992;32:625-632.
5. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 1989;105:221-232.
6. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
7. Humpel C, Weis C. Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices. Implication in Alzheimer's disease? J Neural Transm Suppl 2002:253-263.
8. Hatanaka H, Nihonmatsu I, Tsukui H. Nerve growth factor promotes survival of cultured magnocellular cholinergic neurons from nucleus basalis of Meynert in postnatal rats. Neurosci Lett 1988;90:63-68.
9. Burgos I, Cuello AC, Liberini P, et al. NGF-mediated synaptic sprouting in the cerebral cortex of lesioned primate brain. Brain Res 1995;692:154-160.
10. Lad SP, Neet KE, Mufson EJ. Nerve growth factor, structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Target CNS Neurol Disord 2003;2:315-334.
11. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 1997;9:213-221.
12. Sobreviela T, Clary DO, Reichardt LF, et al. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol 1994;350:587-611.
13. Chao MV, Bothwell MA, Ross AH, et al. Gene transfer and molecular cloning of the human NGF receptor. Science 1986; 232:518-521.
14. Mahadeo D, Kaplan L, Chao MV, Hempstead BL. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J Biol Chem 1994;269:6884-6891.
15. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 2002;67:203-233.
16. Hempstead BL, Martin-Zanca D, Kaplan DR, et al. High-affinity NGF binding requires coexpression of the trk protooncogene and the low-affinity NGF receptor. Nature 1991;350: 678-683.
17. Delcroix JD, Valletta JS, Wu C, et al. NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron 2003;39:69-84.
18. Grimes ML, Zhou J, Beattie EC, et al. Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci 1996;16:7950-7964
19. Ye H, Kuruvilla R, Zweifel LS, Ginty DD. Evidence in support of signaling endosome-based retrograde survival of sympathetic neurons. Neuron 2003;39:57-68.
20. Klesse LJ, Parada LF. Trks: signal transduction and intracellular pathways. Microsc Res Tech 1999;45:210-216.
21. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001;24:1217-1281.
22. Mufson EJ, Ma SY, Dills J, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002;443: 136-153.
23. Mufson EJ, Ma SY, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000;427:19-30.
24. Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999;411:693-704.
25. Hock C, Heese K, Muller-Spahn F, et al. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 1998;241:151-154.
26. Mufson EJ, Lavine N, Jaffar S, et al. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997;146:91-103.
27. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59:198-205.
28. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155.
29. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49:202-213.
30. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 1997;28:307-310.
31. Bennett DA, Shannon KM, Beckett LA, et al. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 1997;49: 1580-1587.
32. Pittman J, Andrews H, Tatemichi T, et al. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis. Arch Neurol 1992; 49:461-467.
33. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
34. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41: 1006-1009.
35. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
36. Rubin EH, Morris JC, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch Neurol 1989;46:379-382.
37. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Rev 3rd ed. Washington, DC: American Psychiatric Association, 1987.
38. Mufson EJ, Ikonomovic MD, Styren SD, et al. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol 2003;60:1143-1148.
39. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
40. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
41. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2.
42. Niero A, Montejo de Garcini E, Avila J. Altered levels of microtubule proteins in brains of Alzheimer's disease patients. Acta Neuropathol (Berl) 1989;78:47-51.
43. Sze CI, Bi H, Kleinschmidt-DeMasters BK, et al. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 2000;175:81-90.
44. 10 β-turn peptidomimetrics. J Org Chem 2004;69:701-713.
45. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62: 6462-6466.
46. Fryer RH, Kaplan DR, Feinstein SC, et al. Developmental and mature expression of full-length and truncated TrkB receptors in the rat forebrain. J Comp Neurol 1996;374:21-40.
47. LeSauteur L, Maliartchouk S, Le Jeune H, et al. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. J Neurosci 1996;16:1308-1316.
48. Holtzman DM, Li Y, Parada LF, et al. p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron 1992;9:465-478.
49. Li Y, Holtzman DM, Kromer LF, et al. Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci 1995;15: 2888-2905.
50. Mufson EJ, Conner JM, Kordower JH. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport 1995;6:1063-1066.
51. Scott SA, Mufson EJ, Weingartner JA, et al. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995;15: 6213-6221.
52. Allen SJ, MacGowan SH, Treanor JJ, et al. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett 1991;131:135-139.
53. Crutcher KA, Scott SA, Liang S, et al. Detection of NGF-like activity in human brain rissue: increased levels in Alzheimer's disease. J Neurosci 1993;13:2540-2550.
54. Cooper JD, Salehi A, Delcroix JD, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001;98: 10439-10444.
55. De Lacalle S, Cooper JD, Svendsen CN, et al. Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats. Neuroscience 1996;75:19-27.
56. Cooper JD, Lindholm D, Sofroniew MV. Reduced transport of [125I]nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience 1994;62:625-629.
57. Salehi A, Ocampo M, Verhaagen J, Swaab DF. P75 neurotrophin receptor in the nucleus basalis of meynert in relation to age, sex, and Alzheimer's disease. Exp Neurol 2000;161: 245-258.
58. Ernfors P, Lindefors N, Chan-Palay V, Persson H. Cholinergic neurons of the nucleus basalis express elevated levels of nerve growth factor receptor mRNA in senile dementia of the Alzheimer's type. Dementia 1990;1:138-145.
59. Mufson EJ, Li JM, Sobreviela T, Kordower JH. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuroreport 1996;8:25-29.
60. Barker PA, Shooter EM. Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells. Neuron 1994;13:203-215.
61. Bamji SX, Majdan M, Pozniak CD, et al. The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. J Cell Biol 1998; 140:911-923.
62. Friedman WJ. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci 2000;20:6340-6346
63. Frade JM, Rodriguez-Tebar A, Barde YA. Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 1996;383:166-168.
64. Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV. Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J Neurosci 1998;18: 3273-3281.
65. Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996;383: 716-719.
66. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001;18:210-220.
67. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer's disease. J Neuropathol Exp Neurol 2004;63:641-649.
68. Fahnestock M, Yu G, Coughlin MD. ProNGF: a neurotrophic or an apoptotic molecule? Prog Brain Res 2004;146:107-110.
69. Rattenholl A, Lilie H, Grossmann A, et al. The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 2001;268: 3296-3303.
70. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001;294: 1945-1948.
71. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Non-tropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA 2001;98: 1941-1946
72. Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991;30:625-636.
73. Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog Brain Res 2004;146:441-449.
74. Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci USA 1999;96: 4067-4072.
75. LeSauteur L, Wei L, Gibbs BF, Saragovi HU. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 1995;270:6564-6569.
76. Maliartchouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol 2000;57:385-391.
77. Bruno M, Seltzer A, Quirion R, et al. Long-lasting rescue of aged-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci (in press).